A Phase 3 interventional study of Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg and Amlodipine 10 mg + Valsartan 160 mg in Hypertension With Hyperlipidemia, sponsored by HK inno.N Corporation. Completed. Open to participants aged 19 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-05-30.
Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
This study's enrollment of 203 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
Drug: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg
Amlodipine 10mg + Valsartan 160mg
Drug: Amlodipine 10 mg + Valsartan 160 mg
Valsartan 160mg + Rosuvastatin 20mg
Drug: Valsartan 160 mg + Rosuvastatin 20 mg
Drug page: Amlodipine
Drug page: Amlodipine
Drug page: Valsartan
Change of LDL-C and siSBP
Mean change from baseline in LDL-C and siSBP at Week 8
Time frame: baseline and 8 weeks
No study locations are listed for this record.
Ran from Oct 2016 to primary completion in Sep 2017, 10 months.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine